Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

Assessment of frequency of regression and progression of mild cervical neoplasia--LGSIL in women with positive high-risk HPV DNA test result.

Pruski D, Fraszczak J, Iwaniec K, Przybylski M, Kedzia W, Gretkiewicz-Tomczyk A, Karowicz-Bilińska A, Spaczyński M.

Ginekol Pol. 2012 Aug;83(8):572-5.

PMID:
23342878
2.

The clinical value of digene hybrid capture HPV DNA testing in a referral-based population with abnormal pap smears.

Recio FO, Sahai Srivastava BI, Wong C, Hempling RE, Eltabbakh GH, Piver MS.

Eur J Gynaecol Oncol. 1998;19(3):203-8.

PMID:
9641214
3.

[Health technology assessment report: HPV DNA based primary screening for cervical cancer precursors].

Ronco G, Biggeri A, Confortini M, Naldoni C, Segnan N, Sideri M, Zappa M, Zorzi M, Calvia M, Accetta G, Giordano L, Cogo C, Carozzi F, Gillio Tos A, Arbyn M, Mejier CJ, Snijders PJ, Cuzick J, Giorgi Rossi P.

Epidemiol Prev. 2012 May-Aug;36(3-4 Suppl 1):e1-72. Italian.

4.

Spontaneous evolution of human papillomavirus infection in the uterine cervix.

Paraskevaidis E, Kalantaridou SN, Georgiou I, Koliopoulos G, Pappa L, Malamou-Mitsi V, Agnantis NJ, Kitchener HC, Lolis DE.

Anticancer Res. 1999 Jul-Aug;19(4C):3473-8.

PMID:
10629638
5.

High-risk cervical epithelial neoplasia grade 1 treated by loop electrosurgical excision: follow-up and value of HPV testing.

Alonso I, Torné A, Puig-Tintoré LM, Esteve R, Quinto L, Garcia S, Campo E, Pahisa J, Ordi J.

Am J Obstet Gynecol. 2007 Oct;197(4):359.e1-6. Epub 2007 Aug 21.

PMID:
17714678
6.

The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.

C Kitchener H, Canfell K, Gilham C, Sargent A, Roberts C, Desai M, Peto J.

Health Technol Assess. 2014 Apr;18(23):1-196. doi: 10.3310/hta18230.

7.

Attributing oncogenic human papillomavirus genotypes to high-grade cervical neoplasia: which type causes the lesion?

van der Marel J, Berkhof J, Ordi J, Torné A, Del Pino M, van Baars R, Schiffman M, Wentzensen N, Jenkins D, Quint WG.

Am J Surg Pathol. 2015 Apr;39(4):496-504. doi: 10.1097/PAS.0000000000000342.

PMID:
25353286
8.

Human Papillomavirus Test for Triage of Japanese Women With Low-Grade Squamous Intraepithelial Lesions.

Iwata T, Hasegawa T, Ochiai K, Takizawa K, Umezawa S, Kuramoto H, Ohmura M, Kubushiro K, Arai H, Sakamoto M, Motoyama T, Watanabe K, Aoki D.

Reprod Sci. 2015 Dec;22(12):1509-15. doi: 10.1177/1933719115589408. Epub 2015 Jun 19.

PMID:
26092278
9.

Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral.

Kulasingam SL, Hughes JP, Kiviat NB, Mao C, Weiss NS, Kuypers JM, Koutsky LA.

JAMA. 2002 Oct 9;288(14):1749-57.

PMID:
12365959
10.
11.

Prediction of recurrence after treatment for high-grade cervical intraepithelial neoplasia: the role of human papillomavirus testing and age at conisation.

Verguts J, Bronselaer B, Donders G, Arbyn M, Van Eldere J, Drijkoningen M, Poppe W.

BJOG. 2006 Nov;113(11):1303-7. Epub 2006 Sep 15.

12.

Human papillomavirus infection and time to progression and regression of cervical intraepithelial neoplasia.

Schlecht NF, Platt RW, Duarte-Franco E, Costa MC, Sobrinho JP, Prado JC, Ferenczy A, Rohan TE, Villa LL, Franco EL.

J Natl Cancer Inst. 2003 Sep 3;95(17):1336-43.

PMID:
12953088
13.

Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.

Castle PE, Stoler MH, Wright TC Jr, Sharma A, Wright TL, Behrens CM.

Lancet Oncol. 2011 Sep;12(9):880-90. doi: 10.1016/S1470-2045(11)70188-7. Epub 2011 Aug 22.

PMID:
21865084
14.

Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities.

Castle PE, Solomon D, Schiffman M, Wheeler CM.

J Natl Cancer Inst. 2005 Jul 20;97(14):1066-71.

PMID:
16030304
15.

Subsequent risk and presentation of cervical intraepithelial neoplasia (CIN) 3 or cancer after a colposcopic diagnosis of CIN 1 or less.

Pretorius RG, Peterson P, Azizi F, Burchette RJ.

Am J Obstet Gynecol. 2006 Nov;195(5):1260-5.

PMID:
17074547
16.

Contribution of human papillomavirus testing by hybrid capture in the triage of women with repeated abnormal pap smears before colposcopy referral.

Fait G, Kupferminc MJ, Daniel Y, Geva E, Ron IG, Lessing JB, Bar-Am A.

Gynecol Oncol. 2000 Nov;79(2):177-80.

PMID:
11063640
17.

Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting.

Leinonen M, Nieminen P, Kotaniemi-Talonen L, Malila N, Tarkkanen J, Laurila P, Anttila A.

J Natl Cancer Inst. 2009 Dec 2;101(23):1612-23. doi: 10.1093/jnci/djp367. Epub 2009 Nov 9.

PMID:
19903804
18.

Human papillomavirus detection by the hybrid capture II assay: a reliable test to select women with normal cervical smears at risk for developing cervical lesions.

Clavel C, Masure M, Levert M, Putaud I, Mangeonjean C, Lorenzato M, Nazeyrollas P, Gabriel R, Quereux C, Birembaut P.

Diagn Mol Pathol. 2000 Sep;9(3):145-50.

PMID:
10976721
19.

Management of women who test positive for high-risk types of human papillomavirus: the HART study.

Cuzick J, Szarewski A, Cubie H, Hulman G, Kitchener H, Luesley D, McGoogan E, Menon U, Terry G, Edwards R, Brooks C, Desai M, Gie C, Ho L, Jacobs I, Pickles C, Sasieni P.

Lancet. 2003 Dec 6;362(9399):1871-6.

PMID:
14667741
20.

High-risk HPV testing in women with borderline and mild dyskaryosis: long-term follow-up data and clinical relevance.

Denise Zielinski G, Snijders PJ, Rozendaal L, Voorhorst FJ, Runsink AP, de Schipper FA, Meijer CJ.

J Pathol. 2001 Oct;195(3):300-6.

PMID:
11673826

Supplemental Content

Support Center